Want to see SE:QCORE full AI Analyst Report?
QCORE Stock Chart & Stats
kr0.50
-kr0.12(-3.11%)
At close: 4:00 PM EST
kr0.50
-kr0.12(-3.11%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr1.00
Previous CloseN/A
Volume1.64K
Average Volume (3M)33.43K
Market Cap
kr18.32M
Enterprise Valuekr10.89
Total Cash (Recent Filing)kr6.06M
Total Debt (Recent Filing)kr1.25M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding42,900,500
10 Day Avg. Volume79,789
30 Day Avg. Volume33,432
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)2.07
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces refinancing and solvency pressure, giving Qlucore greater flexibility while it works to improve operations. A smaller debt burden also limits interest-related cash demands and preserves more capacity to invest in its software platform over the coming quarters.
Revenue RecoveryThe return to TTM revenue growth suggests customer demand may be stabilizing after earlier weakness. If sustained, improved sales provide a foundation for better operating leverage, broader software adoption, and eventual absorption of the company’s currently high fixed cost burden.
Specialized Software OfferingA focused bioinformatics product serving genomics, transcriptomics, and clinical-data analysis gives Qlucore a defined position in research workflows. Its relevance to biomarker discovery and data-driven drug and diagnostics development supports continued use in specialized life-science applications.
Bears Say
Persistent Cash BurnOngoing operating and free-cash-flow deficits mean the business is not currently funding itself from operations. Continued cash consumption can reduce financial resilience and leave Qlucore reliant on external funding or existing balance-sheet resources to sustain development and commercial activity.
Severe Profitability DeteriorationCosts running well above sales indicate that the current operating model is not converting revenue into viable gross economics. Persistent operating and net losses could limit reinvestment, weaken execution capacity, and delay the path to sustainable profitability even if revenue improves.
Shrinking Equity CushionThe substantial decline in equity shows that continuing losses are consuming the company’s capital base. A smaller cushion reduces protection against further operating setbacks and may constrain strategic flexibility, particularly while cash flow remains negative and profitability has deteriorated.
QCORE FAQ
What was Qlucore AB’s price range in the past 12 months?
Qlucore AB lowest stock price was kr0.21 and its highest was kr1.00 in the past 12 months.
What is Qlucore AB’s market cap?
Qlucore AB’s market cap is kr18.32M.
When is Qlucore AB’s upcoming earnings report date?
Qlucore AB’s upcoming earnings report date is Nov 26, 2026 which is in 76 days.
How were Qlucore AB’s earnings last quarter?
Qlucore AB released its earnings results on Sep 09, 2026. The company reported -kr0.067 earnings per share for the quarter.
Is Qlucore AB overvalued?
According to Wall Street analysts Qlucore AB’s price is currently Overvalued.
Does Qlucore AB pay dividends?
Qlucore AB does not currently pay dividends.
What is Qlucore AB’s EPS estimate?
Qlucore AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlucore AB have?
Qlucore AB has 42,900,500 shares outstanding.
What happened to Qlucore AB’s price movement after its last earnings report?
Qlucore AB reported an EPS of -kr0.067 in its last earnings report. Following the earnings report the stock price went down -3.175%.
Which hedge fund is a major shareholder of Qlucore AB?
Currently, no hedge funds are holding shares in SE:QCORE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlucore AB
Based in Lund, Sweden, Qlucore AB (publ) delivers advanced bioinformatics data analysis tools for global application in both scientific research and accurate medical diagnostics. Its product suite includes Qlucore Omics Explorer, an AI-powered bioinformatics software designed for research across various sectors such as life science, biotechnology, food, plant industries, and academia. Additionally, the company offers Qlucore Diagnostics, a specialized software platform for multi-omics companion and precision diagnostics, as well as Qlucore Insights, which facilitates the analysis of clinical data. Qlucore was established in 2007.
Technical Analysis
Precise Biometrics AB
―
AegirBio AB
―
Modelon AB
―
Vitec Software Group AB Class B
―
Carasent AB
―